Aptevo Therapeutics Stock Is Sinking Today - Here's Why
Portfolio Pulse from Vandana Singh
Aptevo Therapeutics Inc announced positive results from its Phase 1b trial of APVO436, a drug candidate for acute myelogenous leukemia (AML). The drug, in combination with venetoclax and azacitidine, achieved a high response rate of 82%. The company also plans to conduct Phase 2 trials for APVO436 in the second half of 2023. Despite the positive news, Aptevo's stock price fell by 25.40%.
July 18, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Despite positive trial results for its AML drug candidate, APVO436, Aptevo Therapeutics' stock price fell by 25.40%.
The positive trial results for APVO436 would typically be expected to boost Aptevo's stock price. However, the stock price fell significantly, suggesting that other factors may be influencing investor sentiment. This could include concerns about the upcoming Phase 2 trials or broader market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100